PL357647A1 - Inhibitory TACE oparte na kwasie acetylenoarylosulfonamido-i-fosfinoamidohydroksamowym - Google Patents

Inhibitory TACE oparte na kwasie acetylenoarylosulfonamido-i-fosfinoamidohydroksamowym

Info

Publication number: PL357647A1
Authority: PL; Poland
Prior art keywords: aryl sulfonamide; tace inhibitors; acid amide; amide hydroxamic; hydroxamic acid
Prior art date: 1999-01-27

Application number

PL00357647A

Other languages

English (en)

Inventor

Jeremy Ian Levin

James Ming Chen

Original Assignee

American Cyanamid Company

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-01-27

Filing date

2000-01-27

Publication date

2004-07-26

2000-01-27 Application filed by American Cyanamid Company filed Critical American Cyanamid Company

2004-07-26 Publication of PL357647A1 publication Critical patent/PL357647A1/pl

Links

NEAQRZUHTPSBBM-UHFFFAOYSA-N 2-hydroxy-3,3-dimethyl-7-nitro-4h-isoquinolin-1-one Chemical compound C1=C([N+]([O-])=O)C=C2C(=O)N(O)C(C)(C)CC2=C1 NEAQRZUHTPSBBM-UHFFFAOYSA-N 0.000 title abstract 2
239000002253 acid Substances 0.000 title 1
125000004421 aryl sulphonamide group Chemical group 0.000 title 1
ACVYVLVWPXVTIT-UHFFFAOYSA-N phosphinic acid Chemical compound O[PH2]=O ACVYVLVWPXVTIT-UHFFFAOYSA-N 0.000 title 1
239000002447 tumor necrosis factor alpha converting enzyme inhibitor Substances 0.000 title 1
GOZMBJCYMQQACI-UHFFFAOYSA-N 6,7-dimethyl-3-[[methyl-[2-[methyl-[[1-[3-(trifluoromethyl)phenyl]indol-3-yl]methyl]amino]ethyl]amino]methyl]chromen-4-one;dihydrochloride Chemical compound Cl.Cl.C=1OC2=CC(C)=C(C)C=C2C(=O)C=1CN(C)CCN(C)CC(C1=CC=CC=C11)=CN1C1=CC=CC(C(F)(F)F)=C1 GOZMBJCYMQQACI-UHFFFAOYSA-N 0.000 abstract 1
208000030507 AIDS Diseases 0.000 abstract 1
206010009900 Colitis ulcerative Diseases 0.000 abstract 1
208000011231 Crohn disease Diseases 0.000 abstract 1
206010040047 Sepsis Diseases 0.000 abstract 1
201000006704 Ulcerative Colitis Diseases 0.000 abstract 1
210000000845 cartilage Anatomy 0.000 abstract 1
230000003412 degenerative effect Effects 0.000 abstract 1
201000010099 disease Diseases 0.000 abstract 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
230000001404 mediated effect Effects 0.000 abstract 1
201000006417 multiple sclerosis Diseases 0.000 abstract 1
201000008482 osteoarthritis Diseases 0.000 abstract 1
206010039073 rheumatoid arthritis Diseases 0.000 abstract 1
-1 rheumatoid arthritis Chemical compound 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
- C07C309/01—Sulfonic acids
- C07C309/28—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
- C07C309/41—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing singly-bound oxygen atoms bound to the carbon skeleton
- C07C309/42—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing singly-bound oxygen atoms bound to the carbon skeleton having the sulfo groups bound to carbon atoms of non-condensed six-membered aromatic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/22—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms
- C07C311/29—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/30—Phosphinic acids [R2P(=O)(OH)]; Thiophosphinic acids ; [R2P(=X1)(X2H) (X1, X2 are each independently O, S or Se)]
- C07F9/36—Amides thereof
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/04—Systems containing only non-condensed rings with a four-membered ring

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
Veterinary Medicine (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Diabetes (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Immunology (AREA)
Rheumatology (AREA)
Molecular Biology (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Pain & Pain Management (AREA)
Endocrinology (AREA)
Dermatology (AREA)
Oncology (AREA)
Virology (AREA)
Hematology (AREA)
Hospice & Palliative Care (AREA)
Orthopedic Medicine & Surgery (AREA)
Ophthalmology & Optometry (AREA)
Biochemistry (AREA)
Urology & Nephrology (AREA)
Transplantation (AREA)
Tropical Medicine & Parasitology (AREA)
Obesity (AREA)
Emergency Medicine (AREA)

PL00357647A 1999-01-27 2000-01-27 Inhibitory TACE oparte na kwasie acetylenoarylosulfonamido-i-fosfinoamidohydroksamowym PL357647A1 (pl)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US23907099A	1999-01-27	1999-01-27
PCT/US2000/002076 WO2000044710A2 (en)	1999-01-27	2000-01-27	Acetylenic aryl sulfonamide and phosphinic acid amide hydroxamic acid tace inhibitors

Publications (1)

Publication Number	Publication Date
PL357647A1 true PL357647A1 (pl)	2004-07-26

Family

ID=22900458

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PL00357647A PL357647A1 (pl)	1999-01-27	2000-01-27	Inhibitory TACE oparte na kwasie acetylenoarylosulfonamido-i-fosfinoamidohydroksamowym

Country Status (20)

Country	Link
EP (1)	EP1144369B1 (pl)
JP (1)	JP2003524617A (pl)
KR (1)	KR20010101733A (pl)
CN (1)	CN1376144A (pl)
AT (1)	ATE271540T1 (pl)
AU (1)	AU769180B2 (pl)
BR (1)	BR0007750A (pl)
CA (1)	CA2356855A1 (pl)
CZ (1)	CZ20012710A3 (pl)
DE (1)	DE60012302T2 (pl)
DK (1)	DK1144369T3 (pl)
EA (1)	EA200100810A1 (pl)
ES (1)	ES2225108T3 (pl)
HU (1)	HUP0200729A3 (pl)
IL (1)	IL144322A0 (pl)
NO (1)	NO20013676D0 (pl)
PL (1)	PL357647A1 (pl)
PT (1)	PT1144369E (pl)
WO (1)	WO2000044710A2 (pl)
ZA (1)	ZA200104507B (pl)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AR022422A1 (es) *	1999-01-27	2002-09-04	American Cyanamid Co	Inhibidores de tace acetilenicos de acido hidroxamico de heteroarilfulfonamida y amida del acido fosfinico
US6465508B1 (en)	2000-02-25	2002-10-15	Wyeth	Preparation and use of ortho-sulfonamido aryl hydroxamic acids as matrix metalloproteinase inhibitors
AR027943A1 (es) *	2000-02-25	2003-04-16	Wyeth Corp	Acidos orto-sulfonamido aril hidroxamicos como inhibidores de metaloproteinasa de matriz y preparacion de los mismos
CA2357110A1 (en) *	2001-04-11	2002-10-11	American Cyanamid Company	Method for the treatment of polycystic kidney disease
US7488754B2 (en)	2002-04-05	2009-02-10	Wyeth	Method for the treatment of polycystic kidney disease
US7199155B2 (en)	2002-12-23	2007-04-03	Wyeth Holdings Corporation	Acetylenic aryl sulfonate hydroxamic acid TACE and matrix metalloproteinase inhibitors
FR2899895B1 (fr) *	2006-04-12	2010-09-17	Servier Lab	Nouveaux sels de strontium d'acides sulfoniques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
EP3860608A1 (en)	2018-10-04	2021-08-11	INSERM (Institut National de la Santé et de la Recherche Médicale)	Egfr inhibitors for treating keratodermas

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
HUP9903916A3 (en) *	1996-08-28	2001-06-28	Procter And Gamble Co Cincinna	Phosphinic acid amides and pharmaceutical compositions containing the same
DE69709160T2 (de) *	1996-10-16	2002-08-14	American Cyanamid Co., Madison	Herstellung und anwendung von ortho-sulfonamido-aryl-hydroxamsäuren als matrix-metalloproteinase- und tace-inhibitoren

2000
- 2000-01-27 HU HU0200729A patent/HUP0200729A3/hu unknown
- 2000-01-27 IL IL14432200A patent/IL144322A0/xx unknown
- 2000-01-27 PL PL00357647A patent/PL357647A1/pl not_active Application Discontinuation
- 2000-01-27 DE DE60012302T patent/DE60012302T2/de not_active Expired - Fee Related
- 2000-01-27 WO PCT/US2000/002076 patent/WO2000044710A2/en not_active Ceased
- 2000-01-27 EA EA200100810A patent/EA200100810A1/ru unknown
- 2000-01-27 JP JP2000595967A patent/JP2003524617A/ja active Pending
- 2000-01-27 EP EP00913270A patent/EP1144369B1/en not_active Expired - Lifetime
- 2000-01-27 PT PT00913270T patent/PT1144369E/pt unknown
- 2000-01-27 KR KR1020017009433A patent/KR20010101733A/ko not_active Withdrawn
- 2000-01-27 CA CA002356855A patent/CA2356855A1/en not_active Abandoned
- 2000-01-27 CN CN00810895A patent/CN1376144A/zh active Pending
- 2000-01-27 ES ES00913270T patent/ES2225108T3/es not_active Expired - Lifetime
- 2000-01-27 BR BR0007750-0A patent/BR0007750A/pt not_active IP Right Cessation
- 2000-01-27 CZ CZ20012710A patent/CZ20012710A3/cs unknown
- 2000-01-27 DK DK00913270T patent/DK1144369T3/da active
- 2000-01-27 AT AT00913270T patent/ATE271540T1/de not_active IP Right Cessation
- 2000-01-27 AU AU34744/00A patent/AU769180B2/en not_active Ceased
2001
- 2001-05-31 ZA ZA200104507A patent/ZA200104507B/en unknown
- 2001-07-26 NO NO20013676A patent/NO20013676D0/no not_active Application Discontinuation

Also Published As

Publication number	Publication date
KR20010101733A (ko)	2001-11-14
DE60012302D1 (en)	2004-08-26
ATE271540T1 (de)	2004-08-15
EP1144369A2 (en)	2001-10-17
DK1144369T3 (da)	2004-11-01
CA2356855A1 (en)	2000-08-03
PT1144369E (pt)	2004-11-30
JP2003524617A (ja)	2003-08-19
ES2225108T3 (es)	2005-03-16
ZA200104507B (en)	2002-08-31
CN1376144A (zh)	2002-10-23
EA200100810A1 (ru)	2002-02-28
CZ20012710A3 (cs)	2002-04-17
AU769180B2 (en)	2004-01-15
HUP0200729A3 (en)	2005-04-28
EP1144369B1 (en)	2004-07-21
DE60012302T2 (de)	2005-08-04
WO2000044710A2 (en)	2000-08-03
BR0007750A (pt)	2001-10-30
WO2000044710A3 (en)	2000-12-21
NO20013676D0 (no)	2001-07-26
AU3474400A (en)	2000-08-18
IL144322A0 (en)	2002-05-23
HUP0200729A2 (hu)	2002-07-29

Legal Events

Date	Code	Title	Description
2009-01-30	REFS	Decisions on refusal to grant patents (taken after the publication of the particulars of the applications)

Publication	Publication Date	Title
WO2000044709A3 (en)	2000-12-21	ACETYLENIC α-AMINO ACID-BASED SULFONAMIDE HYDROXAMIC ACID TACE INHIBITORS
BG105736A (en)	2002-05-31	2,3,4,5-tetrahydro-1h-[1,4]benzodiasepine-3-hydroxamic acid as matrix metalloproteinase inhibitors
TW428018B (en)	2001-04-01	Aminosilane salts and silanamides of carboxylic acids as corrosion inhibitors
HU912299D0 (en)	1991-12-30	Process for producing oligomers and pharmaceutical preparatives containing these compounds
PL350420A1 (en)	2002-12-16	Acetylenic sulfonamide thiol tace inhibitors
IL144322A0 (en)	2002-05-23	Acetylenic aryl sulfonamide and phosphinic acid amide hydroxamic acid as tace inhibitors
EP0727391A3 (en)	1997-04-02	Polymeric salt of dithiocarbamic acid and method of use
NO20004569D0 (no)	2000-09-13	Uorganiske sammensetninger, fremgangsmÕte ved fremstilling og anvendelse derav
BR0007783A (pt)	2002-02-05	Composto, método de inibir mudanças patológicas mediadas pela enzima que converte o tnf-a (tace) em um mamìfero em necessidade deste, composição farmacêutica, e, processos para preparar um composto
DE60144111D1 (de)	2011-04-07	Verfahren zur Verhinderung der Phosphatfällung
DK0745102T3 (da)	2000-09-25	Copolymerer af polyasparaginsyre og polycarboxylsyrer og polyaminer
EA200100808A1 (ru)	2001-12-24	ГИДРОКСАМОВЫЕ КИСЛОТЫ НА ОСНОВЕ АЦЕТИЛЕНОВОГО b-СУЛЬФОНАМИДО И АМИДА ФОСФИНОВОЙ КИСЛОТЫ, КАК ИНГИБИТОРЫ TACE
EP1279674A3 (en)	2003-10-01	Acetylenic ortho-sulfonamido and phosphinic acid amido bicyclic heteroaryl hydroxamic acids as TACE inhibitors
WO2000044740A3 (en)	2001-01-25	Heteroaryl acetylenic sulfonamide and phosphinic acid amide hydroxamic acid tace inhibitors
MXPA04004010A (es)	2004-07-23	Acidos hidroxamicos de aril sulfonamida alenicos como inhibidores de tace y metaloproteinasa de matriz.
WO2003086325A3 (en)	2004-07-01	Cyanamides useful as reversible inhibitors of cysteine proteases
KR970001235A (ko)	1997-01-21	산폐수 중화물질을 이용한 산업폐수 처리방법
ATE281476T1 (de)	2004-11-15	Verfahren zur eliminierung von formamid aus n- vinylformamideinheiten enthaltenden polymerisaten
HUT56550A (en)	1991-09-30	Process for producing 4-chloro-3-sulfamoylbenzoic acid hydrazides and pharmaceutical compositions comprising such compounds